Aligos Therapeutics, Inc. (ALGS)
NASDAQ: ALGS · Real-Time Price · USD
39.84
+1.49 (3.89%)
At close: Dec 20, 2024, 4:00 PM
40.34
+0.50 (1.25%)
After-hours: Dec 20, 2024, 6:36 PM EST
Aligos Therapeutics Stock Forecast
Stock Price Forecast
The 1 analyst with a 12-month price forecast for Aligos Therapeutics stock has a target of 75, which predicts an increase of 88.25% from the current stock price of 39.84.
Analyst Consensus: Strong Buy
* Price targets were last updated on Nov 7, 2024.
Analyst Ratings
According to 1 stock analyst, the rating for ALGS is "Strong Buy". This means that the analyst believes this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 | Dec '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Buy | 1 | 0 | 0 | 0 | 0 | 0 |
| Hold | 1 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 1 | 1 | 1 | 1 | 1 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $75 | Strong Buy | Reiterates | $75 | +88.25% | Nov 7, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $75 | Strong Buy | Reiterates | $75 | +88.25% | Oct 23, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $75 | Strong Buy | Reiterates | $75 | +88.25% | Sep 20, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Initiates $75 | Strong Buy | Initiates | $75 | +88.25% | Aug 19, 2024 |
| Piper Sandler | Piper Sandler | Buy Maintains $75 → $175 | Buy | Maintains | $75 → $175 | +339.26% | Jan 17, 2023 |
Financial Forecast
Revenue This Year
3.82M
from 15.53M
Decreased by -75.40%
Revenue Next Year
1.36M
from 3.82M
Decreased by -64.40%
EPS This Year
-10.75
from -34.11
EPS Next Year
-12.16
from -10.75
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 4.8M | 4.2M | n/a | |||
| Avg | 3.8M | 1.4M | n/a | |||
| Low | 3.3M | n/a | n/a |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | -68.9% | 9.9% | - | |||
| Avg | -75.4% | -64.4% | - | |||
| Low | -79.1% | - | - |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | -10.04 | -8.54 | -7.16 | |||
| Avg | -10.75 | -12.16 | -13.40 | |||
| Low | -11.28 | -17.52 | -19.07 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | - | - | |||
| Avg | - | - | - | |||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.